Schueneman v. Arena Pharmaceuticals, Inc.

CourtDistrict Court, S.D. California
DecidedJune 12, 2020
Docket3:10-cv-01959
StatusUnknown

This text of Schueneman v. Arena Pharmaceuticals, Inc. (Schueneman v. Arena Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schueneman v. Arena Pharmaceuticals, Inc., (S.D. Cal. 2020).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 TODD SCHUENEMAN et al., Case No.: 3:10-CV-01959-CAB-(BLM)

12 Plaintiffs, AMENDED FINAL APPROVAL OF 13 v. CLASS SETTLEMENT AND AWARDS OF ATTORNEYS’ FEES, 14 ARENA PHARMACEUTICALS, INC. et COSTS AND EXPENSES al., 15 [Doc. No. 158, 159] Defendants. 16

17 This matter is before the Court on Lead Plaintiff’s unopposed motion for final 18 approval of class action settlement and Lead Counsel’s motion for an award of attorneys’ 19 fees, costs and expenses. [Doc. Nos. 158, 159.] The Court held a hearing on the motions 20 on April 12, 2018. As discussed below, the motion for final approval is granted, and the 21 motion for attorneys’ fees, costs and expenses is granted in part. 22 I. Background 23 This putative class action lawsuit began on September 20, 2010,1 when a complaint 24 was filed alleging various violations of the Securities Exchange Act of 1934 (“Exchange 25 26

27 1 This is the lead case of a consolidated class action that includes Case Nos. 10cv1961, 10cv1977, 28 1 Act”) and the Securities Act of 1933 (the “Securities Act”). On November 1, 2011, Lead 2 Plaintiff filed a Consolidated Amended Class Action Complaint for violations of the 3 federal securities laws that was subsequently amended on May 13, 2013. [Doc. Nos. 43, 4 59.] 5 On November 7, 2017, after over seven years of pending litigation, including an 6 appeal to the Ninth Circuit, the parties notified the Court that they had reached a settlement. 7 [Doc. Nos. 152, 153.] 8 The Stipulation and Agreement of Settlement (“Settlement”) provides for settlement 9 and full release of all claims against Defendants2 for securities fraud violations. It 10 authorizes a recovery of $24,000,000, consisting of $12,025,000 in cash and Arena 11 common stock to be issued with a value of $11,975,000 (“Settlement Shares”)3. [Doc. No. 12 154 at ¶ 1.24.] The Settlement defines the class as “all Persons who purchased Arena 13 common stock between March 17, 2008 and January 27, 2011, inclusive, and were 14 damaged thereby.” [Doc. No. 154 at ¶ 1.26.] The average distribution is estimated to be 15 $0.13 per damaged share before deduction of Court-approved fees and expenses. [Doc. 16 No. 160-2 at 94.] The Net Settlement Fund shall be distributed to Authorized Claimants as 17 proscribed by the Plan of Allocation, with each claimant’s share of the Net Settlement Fund 18 being based upon the recognized loss formula described in the Notice [Doc. No. 154 at ¶ 19 1.20; Doc. No. 160-2 at 21-26.] Additionally, the settlement authorizes: (1) payment of up 20 to $250,000.00 in class administrator fees; (2) the payment of taxes and tax expense; (3) a 21 fee and expense award to lead counsel; and (4) payment of a class representative award. 22 [Doc. No. 154 at ¶¶ 3.11, 6.4, 7.1, 7.2.] The separately filed motion for attorneys’ fees 23 informs that Lead Counsel is seeking 30 percent of the cash consideration and 30 percent 24

25 26 2 The “Defendants” are Arena Pharmaceuticals, Inc. (the “Company”), Jack Lief, Robert E. Hoffman, Dominic P. Behan, William R. Shanahan, and Christy Anderson. 27 3 Arena has the option to pay all or part of the Settlement Shares in cash at the time Arena is to issue the Settlement Shares. [See Doc. No. 152, ¶ 3.4.] 28 1 of the Settlement Shares, reimbursement of $251,213.10 in litigation expenses, and a 2 $17,500 representative award for Lead Plaintiff. [Doc. No. 159.] 3 On November 7, 2017, Lead Plaintiff filed an unopposed motion for preliminary 4 approval of the settlement. [Doc. No. 153.] The Court granted the motion and 5 preliminarily approved the settlement on November 20, 2017. [Doc. No. 156.] The 6 preliminary approval order set a final approval hearing for April 12, 2018. The final 7 approval hearing took place as scheduled. Counsel for both parties attended. No class 8 members filed objections to the settlement, and no class members attended the hearing. 9 However, two class member requested exclusion from the settlement. 10 II. Final Approval of Settlement 11 A. Certification of the Settlement Class 12 The settlement here envisions certification of a class of “all Persons who purchased 13 Arena common stock between March 17, 2008 and January 27, 2011, inclusive, and were 14 damaged thereby.” [Doc. No. 154 at ¶ 1.26.] 15 When considering a motion for approval of a Rule 23 class action the Court must 16 perform the threshold task of certifying the class. See generally Millan v. Cascade Water 17 Servs. Inc., 310 F.R.D. 593, 602-607 (E.D. Cal. 2015). The Court must “ascertain whether 18 the proposed settlement class satisfies the requirements of Rule 23(a) of the Federal Rules 19 of Civil Procedure applicable to all class actions, namely: (1) numerosity, (2) commonality, 20 (3) typicality, and (4) adequacy of representation.” Hanlon v. Chrysler Corp., 150 F.3d 21 1011, 1019 (9th Cir. 1998). Additionally, the Court must determine whether class counsel 22 is adequate and whether “the action is maintainable under Rule 23(b)(1), (2), or (3).” In re 23 Mego Fin. Corp. Sec. Litig., 213 F.3d 454, 462 (9th Cir. 2000) (quoting Amchen Prod. v. 24 Windsor, 521 U.S. 591, 614 (1997)). 25 1. Numerosity 26 This requirement is satisfied if the class is “so numerous that joinder of all members 27 is impracticable.” Fed. R. Civ. P. 23(a)(1). “A class greater than forty members often 28 satisfies this requirement. . . .” Waller v. Hewlett-Packard Co., 295 F.R.D. 472, 482 (S.D. 1 Cal. 2013) (citing Californians for Disability Rights, Inc. v. Cal. Dep’t of Transp., 249 2 F.R.D. 334, 346 (N.D. Cal. 2008)). Here, notice packets were mailed to 139,542 potential 3 class members. Joinder of all these potential plaintiffs would be impracticable. 4 Accordingly, this requirement has been met. 5 2. Commonality 6 This requirement is satisfied if “there are questions of law or fact common to the 7 class.” Fed. R. Civ. P. 23(a)(2). “To satisfy this commonality requirement, plaintiffs need 8 only point to a single issue common to the class.” Vasquez v. Coast Valley Roofing, Inc., 9 670 F. Supp. 2d 1114, 1121 (E.D. Cal. 2009). Here, the commonality requirement is 10 satisfied because all of the class claims involve common questions of law and fact 11 surrounding Defendants’ purported violations of the federal securities laws as evidenced 12 by their alleged failure to disclose material facts regarding the development of the weight 13 loss drug Lorcaserin to investors and by the making of false and misleading statements 14 about the drug. 15 3. Typicality 16 This requirement is satisfied if “the claims or defenses of the representative parties 17 are typical of the claims or defenses of the class.” Fed. R. Civ. P. 23(a)(3). “The test of 18 typicality is whether other members have the same or similar injury, whether the action is 19 based on conduct which is not unique to the named plaintiffs, and whether other class 20 members have been injured by the same course of conduct.” Hanon v. Dataproducts Corp., 21 976 F.2d 497, 508 (9th Cir. 1992) (internal quotations and citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
JOM, Inc. v. Adell Plastics, Inc.
151 F.3d 15 (First Circuit, 1998)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Jack W. Friend v. Ronald Kolodzieczak
72 F.3d 1386 (Ninth Circuit, 1995)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Ginger McCall v. Facebook, Inc.
696 F.3d 811 (Ninth Circuit, 2012)
Boyd v. Bechtel Corp.
485 F. Supp. 610 (N.D. California, 1979)
In Re Omnivision Technologies, Inc.
559 F. Supp. 2d 1036 (N.D. California, 2008)
Vasquez v. Coast Valley Roofing, Inc.
670 F. Supp. 2d 1114 (E.D. California, 2009)
Maley v. Del Global Technologies Corp.
186 F. Supp. 2d 358 (S.D. New York, 2002)
In Re MicroStrategy, Inc. Securities Litigation
148 F. Supp. 2d 654 (E.D. Virginia, 2001)
Theodore H. Frank v. Netflix, Inc.
779 F.3d 934 (Ninth Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Schueneman v. Arena Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/schueneman-v-arena-pharmaceuticals-inc-casd-2020.